Cargando…
Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric Cancers
PURPOSE: Circulating tumor DNA (ctDNA) analyses allow for postoperative risk stratification in patients with curatively treated colon and breast cancers. Use of ctDNA in esophagogastric cancers (EGC) is less characterized and could identify high-risk patients who have been treated with curative inte...
Autores principales: | Huffman, Brandon M., Aushev, Vasily N., Budde, Griffin L., Chao, Joseph, Dayyani, Farshid, Hanna, Diana, Botta, Gregory P., Catenacci, Daniel V.T., Maron, Steven B., Krinshpun, Shifra, Sharma, Shruti, George, Giby V., Malhotra, Meenakshi, Jurdi, Adham, Moshkevich, Solomon, Aleshin, Alexey, Kasi, Pashtoon M., Klempner, Samuel J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10530958/ https://www.ncbi.nlm.nih.gov/pubmed/36480779 http://dx.doi.org/10.1200/PO.22.00420 |
Ejemplares similares
-
Using Tumor-Informed Circulating Tumor DNA (ctDNA)-Based Testing for Patients with Anal Squamous Cell Carcinoma
por: Azzi, Georges, et al.
Publicado: (2022) -
Circulating tumor DNA (ctDNA) serial analysis during progression on PD-1 blockade and later CTLA-4 rescue in patients with mismatch repair deficient metastatic colorectal cancer
por: Kasi, Pashtoon Murtaza, et al.
Publicado: (2022) -
BESPOKE study protocol: a multicentre, prospective observational study to evaluate the impact of circulating tumour DNA guided therapy on patients with colorectal cancer
por: Kasi, Pashtoon Murtaza, et al.
Publicado: (2021) -
Post-operative ctDNA monitoring in stage I colon cancer: A case report
por: Alden, Stephanie L., et al.
Publicado: (2022) -
FGFR2‐Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape
por: Klempner, Samuel J., et al.
Publicado: (2019)